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Abstract
Mature heart valves are complex structures consisting of three highly organized extracellular
matrix layers primarily composed of collagens, proteoglycans and elastin. Collectively, these
diverse matrix components provide all the necessary biomechanical properties for valve function
throughout life. In contrast to healthy valves, myxomatous valve disease is the most common
cause of mitral valve prolapse in the human population and is characterized by an abnormal
abundance of proteoglycans within the valve tri-laminar structure. Despite the clinical
significance, the etiology of this phenotype is not known. Scleraxis (Scx) is a basic-helix-loop-
helix transcription factor that we previously showed to be required for establishing heart valve
structure during remodeling stages of valvulogenesis. In this study, we report that remodeling
heart valves from Scx null mice express decreased levels of proteoglycans, particularly chondroitin
sulfate proteoglycans (CSPGs), while overexpression in embryonic avian valve precursor cells and
adult porcine valve interstitial cells increases CSPGs. Using these systems we further identify that
Scx is positively regulated by canonical Tgfβ2 signaling during this process and this is attenuated
by MAPK activity. Finally, we show that Scx is increased in myxomatous valves from human
patients and mouse models, and overexpression in human mitral valve interstitial cells modestly
increases proteoglycan expression consistent with myxomatous mitral valve phenotypes. Together,
these studies identify an important role for Scx in regulating proteoglycans in embryonic and
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mature valve cells and suggest that imbalanced regulation could influence myxomatous
pathogenesis.
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1. Introduction
The mature mitral valve leaflets are composed of three stratified layers of specialized
extracellular matrix (ECM) interspersed with valve interstitial cells (VICs) [1]. The role of
the ECM is to provide all the necessary biomechanical properties to withstand constant
changes in hemodynamic force during the cardiac cycle. Within the atrioventricular valves,
the fibrosa is located furthest away from blood flow and is predominantly comprised of
parallel bundles of fibrillar collagens that provide tensile strength. In contrast, elastic fibers
within the atrialis layer adjacent to blood flow, allows for flexibility and extensibility. In
between these layers is the spongiosa, rich in proteoglycans with a lower abundance of
collagens, thereby providing a more compressible matrix. Patterning of the heart valves is
initiated during embryonic development and requires extensive remodeling of the
endocardial cushions throughout valvulogenesis and into post natal stages [1]. Although the
ECM composition of the mature tri-laminar valve has been well described, little is known
about the molecular mechanisms that establish and maintain this highly organized structure.
This is of clinical significance as alterations in patterning have detrimental effects on valve
function and are characteristic of disease.
Mitral valve prolapse affects approximately 5% of the human population and is
characterized by abnormal bulging of the mitral valve leaflets into the left atrium during
ventricular systole [2]. Myxomatous degeneration is the most common cause of mitral valve
prolapse and the only effective treatment is surgical repair. Histologically, myxomatous
valve leaflets are pathologically thickened with alterations in the distribution of ECM
components within the tri-laminar connective tissue layers. This includes disrupted collagen
fiber organization [3], elastic fiber fragmentation [4] and most prominent, excess
accumulation of proteoglycans including Biglycan and Decorin throughout [5–7]. These
changes in valve composition weaken the biomechanical properties of the valve resulting in
‘floppy’ leaflets that fail to coapt, leading to regurgitation. The etiology of mitral valve
prolapse is complex and studies have shown linkage to connective tissue disorders and
specific mutations in ECM genes (reviewed [1]). Therefore, due to the heritable nature of
this disease, it is considered that defects in embryonic valve development could underlie
phenotypes observed in the adult population.
Scleraxis (Scx) is a bHLH transcription factor first reported for its expression pattern in
developing somites and limb buds [8]. Additional studies in the chick have shown that Scx
positively promotes tendon cell fate of mesenchymal precursor cells in these two tissues [9–
13]. Known signaling pathways that regulate Scx are limited, with previous reports
describing only Transforming growth factor-β (Tgfβ)-Smad [14] and mitogen-activated
protein kinase (MAPK) [15] as upstream regulators in cardiac fibroblasts [14] and
developing somites [15], respectively. Mice null for Scx develop severe defects in force-
transmitting and intermuscular tendons associated with reduced and disorganized ECM [16].
This observation is likely attributed to reported roles that Scx plays in regulating tendon
progenitor cell differentiation [16] and transcriptional activity of matrix proteins including
type Ia2 collagen (COL1A2) [14, 17]. Our previous work has shown that in developing
valves, Scx is expressed at low levels in mesenchyme valve precursor cells of the
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endocardial cushions, however expression is increased during cushion remodeling and tri-
laminar stratification after birth [18]. Heart valves from Scx−/− mice are abnormally thick
with defects in valve precursor cell differentiation and ECM organization [18], similar to
observations in affected tendons [16]. Together, these studies identify important roles for
Scx in regulating the development of connective tissues in structures of high mechanical
demand.
In a previous study from our lab we described structural defects associated with loss of ECM
stratification in heart valves from Scx−/− mice [18]. In this current study we report that valve
phenotypes observed in Scx−/− mice are largely attributed to a significant decrease in the
expression and contribution of chondroitin sulfate proteoglycans (CSPGs) to the mature
valve leaflets. To examine the mechanisms of Scx-mediated CSPG regulation, we
manipulated Scx function and canonical and non-canonical Tgfβ signaling pathways in
embryonic avian valve precursor cells and mature porcine VICs in vitro. Using these
approaches we show that Scx is sufficient to promote CSPG expression in both embryonic
and mature valve cells thereby promoting a molecular profile similar that observed in
myxomatous mitral valve disease. In addition, Scx is increased in VICs and mitral valves
isolated from human patients and mouse models of myxomatous disease. We further
delineate that Scx-mediated regulation of CSPGs is positively regulated upstream by
canonical Tgfβ-Smad signaling, while activated MAPK attenuates this pathway in a Tgfβ-
independent manner. Findings from this study provide new mechanistic insights into the role
of Scx in the regulation of CSPGs in heart healthy valve leaflets and raises interest for Scx
function in the pathogenesis of myxomatous valve disease.
2. Materials and Methods
2.1 Mouse tissue collection
Scx−/− and Scx+/+ littermate mice were generated as previously described [16, 18], and
collected at embryonic (E) day 16.5, counting day E0.5 by evidence of a copulation plug.
For histology, hearts were dissected in 1X phosphate-buffered saline (PBS) and fixed in 4%
paraformaldehyde (PFA)/PBS overnight at 4°C. After fixation, hearts were processed for
paraffin wax embedding and sectioned at 8µm for immunohistochemistry [18].
Alternatively, atrioventricular canal (AVC) tissue was dissected from unfixed hearts at
postnatal day 1 and RNA extracted using Trizol. Fbn1C1039G/C1039G and Fbn1C103G/+, and
Fbn1+/+ (wild type) mice were generated as described [19], and RNA isolated from AVC
tissue dissected from hearts at postnatal day 6.5. Tgfβ2−/−, Tgfβ2−/+, and Tgfβ2+/+ mice were
generated and genotyped as described [20], and RNA was extracted from whole hearts at
E13.5. All animal procedures were approved and performed in accordance with The
Nationwide Children’s Hospital Research Institute IACUC guidelines.
2.2 Heart Valve Explant Cultures
Mitral and tricuspid valves were dissected from hearts of Scx+/−, and Scx+/+ (wild type) mice
at postnatal day 1 and cultured as explants on pore filters as previously described [21]. At
the time of culture, BSA or 200 pM Tgfβ2 was added to the growth media [22] and explants
were cultured for a further 48 hours. Following treatment, RNA was collected using
standard Trizol protocols.
2.3 Generation of adenovirus
Full length mouse Scx was amplified from E14.5 mouse limb genomic DNA using PCR
designed to add FLAG at the 5’ end: 5’-C TGG ATC CGC CAC CATG GAC TAC AAG
GAC GAC GAT GAC AAA TCC TCC GCC ATG CTG CGT TCA G and 3’-CGT GAA
TTC TCA ACT TCG AAT CGC CGT CTT TCT G. The underlined sequence encodes the
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FLAG (DYKDDDDK) tag. Scx-FLAG was cloned into the pShuttle-IRES-hrGFP-1 vector
and adenoviral Scx-FLAG (AdV-Scx-FLAG) was produced and tittered using the AdEasy-
XL and AdEasy Viral Titer kits according to manufacturer’s instructions (Stratagene).
2.4 Endocardial cushion chicken valve precursor cell cultures
Fertilized White Leghorn chicken eggs (Charles River Laboratories) were incubated in high
humidity at 38°C, and embryonic hearts were collected at Hamburger Hamilton (HH) stage
25. Atrioventricular endocardial cushions were dissected away from the adjacent
myocardium and cultured as described [22]. Following 72 hours of culture, valve precursor
cells were infected with 1.5×109 PFU AdV-GFP, 3.5×107 PFU constitutively active MEK1
(AdV-caMEK1), or 8.5×108 PFU dominant negative MEK1 (AdV-dnMEK1) in serum-free
media for a time-course of 4, 16, and 48 hours. Adenoviruses were obtained from Dr. Jeff
Molkentin, Cincinnati Children’s Hospital Medical Center (Seven Hills Bioreagents) [23,
24]. For Scx gain-of-function studies, cultures were infected for 48 hours with AdV-Scx-
FLAG or AdV-GFP control. For growth factor studies, cultures were treated with 200pM
Tgfβ2 (Sigma) or BSA vehicle control for 30 minutes and 48 hours in normal growth media.
Following treatment, protein and RNA were collected using standard protocols (see below),
or cells were fixed in 4% PFA for 30 minutes at room temperature.
2.5 Murine C3H10T1/2 and NIH3T3 cell cultures
C3H10T1/2 and NIH3T3 cells were obtained from the American Type Culture Collection
and maintained in growth media as recommended. 70% confluent cultures were treated with
200pM Tgfβ2 or BSA vehicle control for 48 hours in normal growth media. For MEK
rescue studies, C3H10T1/2 cell cultures were pre-treated with AdV-caMEK1, AdV-
dnMEK1, or AdV-GFP for 6 hours in serum-free media (as above). Following infection,
media was removed and replaced with normal growth media supplemented with 200pM
Tgfβ2 or BSA vehicle control for 48 hours. After treatments, RNA and was collected using
standard protocols, or cells were fixed in 4% PFA for 30 minutes at room temperature (see
details below).
2.6 Human mitral valve interstitial cell (hMVIC) cultures
Mitral valve tissue was collected from four control patients rejected for transplantation and
three myxomatous mitral valve prolapse (MMVP) patients during elective surgery. Human
mitral VIC cultures were established and maintained in serum-supplemented EBM media as
described [25]. Cells were passaged to P7 and used for in vitro studies. Control cells were
seeded in 6-well plates to ~70% confluency and infected with 4×108 PFU AdV-GFP (Seven
Hills Bioreagents) or 1.6×107 PFUAdV-Scx-FLAG. The differences in these PFU values are
based upon the consistent infection efficiencies of 76.17%±4.12% (AdV-GFP) and 78.27%
±2.67% (AdV-Scx). 48 hours post-infection, RNA was collected using standard protocols
(see below). Additionally, untreated human MVICs from control and MMVP patients were
plated for 48 hours and RNA was isolated using Trizol.
2.7 Porcine valve interstitial cell cultures
Porcine valve interstitial cells were isolated as previously described [26] and plated on
collagen-coated chamber slides to ~80% confluency. Cultures were infected with AdV-GFP
or AdV-Scx-FLAG in serum-free media, or 200pM Tgfβ2 or BSA vehicle control in normal
growth media for 48 hours. Following treatment, cultures were fixed with 4% PFA for 30
minutes at room temperature and subjected to immunohistochemistry (see below).
Barnette et al. Page 4
J Mol Cell Cardiol. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2.8 RNA isolation, cDNA synthesis, and quantitative PCR
mRNA was isolated using Trizol (Invitrogen) as previously described [27] and cDNA was
generated from 200–300ng mRNA using high capacity RNA-to-DNA kit according to
manufacturer’s instructions (Applied Biosystems). 1µl cDNA was subject to quantitative
PCR amplification (StepOne Plus, Applied Biosystems) using specific primers targeting
chicken, mouse, and human mRNAs listed below. In addition, Taqman probes (Applied
Biosystems) were used to target human, murine, and chicken Scx. Following PCR analyses,
the cycle count threshold (Ct) was normalized to species specific housekeeping genes
(GAPDH chicken, L7 mouse, and 18S human) and the ΔCt and fold changes in experimental
samples over controls was determined [27]. Statistically significant differences in gene
expression levels were determined using Student’s t-test or one-way ANOVA plus a post-
hoc test as indicated in the figure legend, on at least 3 independent experiments with p<0.05
considered significant.
PCR primer sequences
Gene Sequence (5’ to 3’)
Perlecan Mouse: F-5’-GCTGCTAGCGGTGACGCATGG-3’
R: 5’-ACTGTGCCCAGGCGTCGGAA-3’
Lumican Mouse: F: 5’-CTGACCGAGTCCGTCGGTCCA-3’
R: 5’-CCGTCGAAGGAGCCGAGCTT-3’
Brevican Mouse: F: 5’-CGACAGTGCCAGCCACGGTG-3’
R: 5’-GCCTGGCAAACATAGGCAGCGG-3’
Neurocan Mouse: F: 5’-CGGCCTGAATGACCGGACAGTAGA3’
R: 5’-CGCCCACTCTCATGTGCCACC-3’
Decorin Chicken: F: 5’-GCCACGCGGTTCCACCAGAA-3’
R: 5’-CAGCGGAAGGGGCACACTGG-3’
Mouse: F: 5’-GGTGTCAGCTGGATGCGCTCAC
R: 5’-TGCAGCCCAGGCAAAAGGGTT-3’
Human: F: 5′-CTGGGCTGGACCG TTTCAAC-3’
R: 5′-GATGGCATTGACAGCGGAAGG-3’
Biglycan Mouse: F: 5’-TTACTGACCGCCTGGCCATCCA-3’
R: 5’-TGCTTAGGAGTCAGGGGGAAGCTGT-3’
Human: F: 5′-ACACCATCAACCGCCAGAGTC-3’
R: 5′-GACAGCCACCGACCTCAGAAG-3’
Aggrecan Mouse: F: 5’-GCTGCCCCTGCCCCGTAATG-3’
R: 5’-AGTCCGGCCCACGTGTGACT-3’
Human: F: 5′-TGCGTGGGTGACAAGGACAG-3’
R: 5′-CAAGGCGTGTGGCGAAGAAC-3’
Fibromodulin Mouse: F: 5’-CTGCCACATTCTCCAACCCAAGG
R: 5’-AGGACGGAGGCCCACTGCATT-3’
Human: F: 5′-GGCTGCTCTGGATTGCTCTC-3’
R: 5′-CGGGTCAGGTTGTTGTGGTC-3’
Versican Chicken: F: 5’-CGGCTGAGAGAGAATGCCGCC
R: 5’-TCCGGCTGGTTTGGTCGCCA-3’
Mouse: F: 5’-GCTGCCCCGAGCCTTTCTGG
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Gene Sequence (5’ to 3’)
R: 5’-GCGCTTGGCCACAGCACCTC-3’
Human: F: 5′-ATCTGGATGGTGATGTGTTC-3’
R: 5′AATCGCACTGGTCAAAGC-3’
Collagen Ia2 Human: F: 5′-CGTGGCAGTGATGGAAGTGTG-3’
R: 5′-ACCAGCAGGACCAGCGTTAC-3’
Collagen IIa1 Human: F: 5′-TGGAGCAGCAAGAGCAAGGAG-3’
R: 5′-CGTGGACAGCAGGCGTAGG-3’
18S Human: F: 5′-AACGATGCCAACTGGTGATGC-3’
R: 5′-CTCCTGGTGGTGCCCTTCC-3’
2.9 Western blotting
Avian valve precursor and C3H10T1/2 cells were lysed in sample buffer (1X SDS buffer,
62.5mM Tris pH 7.5, 1X EDTA-free protease inhibitor cocktail (Roche)). 15–20µg of total
protein for each experimental sample was run on 12% Tris-Glycine SDS PAGE gel
(BioRad) and transferred to 0.45µm nitrocellulose membranes (BioRad) at 300mA for 1.5
hrs. Membranes were blocked in 3% bovine serum albumin (BSA, Millipore) for 1hr and
probed with antibodies against CS-56 (CSPG) (1:1000, 4°C overnight, Sigma), Actin/
Tubulin (1:5000, 1hr room temperature, Chemicon/Millipore), di-phospho-ERK1/2 Thr202/
Tyr204 (dpERK1/2) (1:1000, 4°C overnight, Cell Signaling), or phospho-Smad2 (pSmad
465/467)(1:1000, 4°C overnight, Cell Signaling) in 1.5% BSA, followed by incubation with
anti-mouse- or anti-rabbit-horseradish peroxidase-conjugated secondary antibody (1:15000,
1hr room temperature, Cell Signaling). Membranes were then washed three times in 1x
TBST for 10 minutes and developed using Super Signal West Femto Substrate (Pierce) and
BioMax MR film (Eastman Kodak). Band densities were calculated from at least 3
biological replicates and normalized to loading controls using Image Pro Plus software.
2.10 Immunofluorescence
Fixed avian valve precursor, porcine aortic valve interstitial, and C3H10T1/2 cell cultures
were washed twice in 1X PBS and blocked (2% horse serum, 2%BSA, 0.1% NP-40/PBS)
for 1hr at room temperature. CS-56 antibody to detect CSPG expression was diluted (1:200,
Sigma) in 1:1 blocking solution/PBS, and cells were incubated for 4°C overnight. Cells were
washed 3 times in 1X PBS and incubated with Alexa anti-mouse-568 secondary antibody
(1:400, 1 mg/ml, Molecular Probes) for 1hr at room temperature. Cells were then washed,
stained with DAPI for 10 mins at room temperature and mounted in Vectorshield
(VectorLabs). Fluorescent immunoreactivity was visualized using Olympus BX60
microscope, and captured using CellSens imaging software. Immunoreactivity was
quantitated using Image Pro Plus software and calculated as the intensity sum of Alexa-568
positive CSPGs, over the total number of DAPI-positive stained nuclei.
3. Results
3.1 Proteoglycan expression is attenuated in heart valves from embryonic and post natal
Scx−/− mice
We have previously shown that Scx−/− mice develop valve phenotypes associated with
alterations in connective tissue organization [18]. As proteoglycans are highly abundant
within valves particularly within the spongiosa, we examined if expression was affected in
Scx null mice using a combination of qPCR and immunohistochemistry (IHC). In
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atrioventricular canal regions from post natal Scx−/− mice, expression of keratin sulfates
(lumican, fibromodulin) and chondroitin sulfate proteoglycans (CSPG) (brevican, neurocan,
decorin, biglycan) were all significantly downregulated compared to wild type (Scx+/+)
controls. No significant changes were observed in perlecan (heparin sulfate proteoglycan),
aggrecan or versican (CSPGs) (Figure 1A). Additional IHC analysis using a pan-CSPG
antibody revealed decreased and punctate expression patterns of CSPGs within remodeling
mitral valve leaflets of post natal Scx−/− pups (Figures 1B–C). Similar findings were
observed in Scx−/− mice at E15.5 and 3 months of age (data not shown). Normal
extracellular CSPG immunoreactivity was observed in regions where Scx is not normally
expressed (atria shown in Figure 1D–E). These analyses suggest that Scx is important for
expression of proteoglycans in developing heart valves.
3.2 Scx overexpression in embryonic heart valve precursor cells and adult valve interstitial
cells leads to increased CSPG expression
Our in vivo data shows that loss of Scx leads to decreased expression of proteoglycans,
including CSPGs (Figure 1). To determine if Scx gain of function is sufficient to promote
CSPG expression, we utilized established embryonic avian valve precursor and adult
porcine valve interstitial cell in vitro systems [22, 28]. In the avian system, atrioventricular
endocardial cushions are isolated away from the adjacent myocardium of HH Stage 25 chick
embryos, and mesenchyme valve precursor cells within the cushions are cultured as a
monolayer in the absence of cell-cell contact. At this stage, the valve precursor cells do not
express high levels of Scx and are considered undifferentiated [22]. In the porcine model,
valve cells are isolated from juvenille pigs and are therefore considered mature
myofibroblast-like interstitial cells. Using these embryonic and adult valve cells model
systems, we overexpressed Scx by infecting with a GFP-labeled adenovirus containing full
length FLAG-tagged mouse Scx cDNA (AdV-Scx-FLAG) for 48 hours. As a control, cells
were infected with empty GFP-labeled adenovirus (AdV-GFP). Consistent with our loss of
function studies, gain of function in vitro leads to increased CSPG expression as observed
by Western blot analysis of CSPG expression in avian valve precursor cells (Figure 2A–B)
and immunostaining in porcine valve interstitial cells (VICs) (Figure 2C–E). These studies
suggest that in both embryonic and mature valve cells Scx is sufficient to promote CSPG
expression in vitro.
3.3 Scx and CSPG expression is positively regulated by Tgfβ2
Previous studies have shown that Scx is positively regulated by Tgfβ signaling in fibroblasts
and tenocytes [14, 17, 29–31]. However conserved mechanisms in the valve have not been
reported. To address this, avian valve precursor cells were treated with 200pM Tgfβ2 for 48
hours and Scx expression was examined. As shown in Figure 3A, Scx is increased 1.7-fold
(±0.14) in treated valve precursor cells, and this pattern was also observed in similarly
treated murine mesenchymal C3H10T1/2 (54.3-fold ±2.96) and mouse fibroblast NIH3T3
(8.2-fold ±1.21) cell lines. In support of the positive regulation of Scx by Tgfβ2, qPCR
analysis shows decreased Scx mRNA levels in hearts isolated from E13.5 Tgfβ2+/− and Tgfβ
2−/− mice (Figure 3B). To further determine if Tgfβ2-mediated Scx expression promotes
CSPG expression, immunostaining was performed in treated avian valve precursor cells
(Figure 3C, D, G) and porcine VICs (Figure 3E, F, H). Consistent with Scx overexpression
studies (Figure 2), Tgfβ2 is sufficient to promote CSPG expression in embryonic and mature
valve cells. Mitral valve explants from PND1 Scx+/+ and Scx+/− mice were also subjected
Tgfβ2 treatment to examine the requirement of Scx for Tgfβ2-mediated regulation of
CSPGs. Of the CSPGs examined (decorin, lumican, versican, biglycan), only aggrecan
expression was significantly increased in response to Tgfβ2 treatment and this was not
observed in Scx+/− treated explants (Figure 3I). Together, these data show that Tgfβ-
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mediated regulation of Scx is conserved in heart valves, and this pathway is sufficient to
promote CSPG expression.
3.4 MAPK signaling attenuates Tgfβ2-mediated Scx regulation
Studies have shown that Tgfβ treatment of myofibroblasts is mediated through canonical
Smad(2) signaling, and Smad3 functionally interacts with Scx to regulate activity of target
genes including COL1A2 [14, 17]. In this study we show that Tgfβ2 treatment of avian valve
precursor cells similarly increases pSmad2 expression after 30 minutes (Figure 4A). In
addition to Smads we, and others have shown that Scx can also be regulated by MAPK
signaling in valve precursor cells and developing somites [15, 22, 32]. As Tgfβ can signal
through non-canonical MAPK pathways, we examined expression levels of di-phospho
ERK1/2 Thr202/Tyr204 (dpERK1/2) as an indicator of MAPK activity. By Western blot,
significant changes in dpERK1/2 expression were not observed following Tgfβ2 treatment,
further suggesting that Smad is the downstream effector of Tgfβ2 signaling in the regulation
of Scx in this system. However, when C3H10T1/2 cells were co-treated with an adenovirus
of constitutively active MEK1 (AdV-caMEK1) [24] a known downstream effector of
ERK1/2 for 6 hours prior to Tgfβ2 treatment, Scx expression was significantly attenuated
compared to Tgfβ2 treatment alone (Figure 4B). Similar co-treatment with a dominant
negative MEK1 (dnMEK1) adenovirus (AdV-dnMEK1) [23] for 6 hours had no effect on
the ability of Tgfβ2 to promote Scx. C3H10T1/2 cells were chosen for these studies as they
exhibit embryonic mesenchymal cell phenotypes similar to valve precursor cells [33]. It
therefore appears that Tgfβ2-Smad signaling positively regulates Scx expression, and Tgfβ2-
independent MAPK activity can repress this pathway.
3.5 MAPK signaling negatively regulates Scx in heart valve precursor cells
Our data shows that MAPK signaling represses Tgfβ2-mediated regulation of Scx. To
examine if MAPK activity regulates Scx in the absence of exogenous Tgfβ2, avian valve
precursor cells were subject to infection with AdV-caMEK1 and AdV-dnMEK1 for 48
hours. As confirmed by Western blot, 48 hour AdV-caMEK1 and AdV-dnMEK1 treatments
successfully increased and decreased dpERK1/2 respectively in valve precursor cells (Figure
5A). Only one band was observed when detecting dpERK1/2 Thr202/Tyr204, consistent
with previous reports using the same avian valve precursor cell culture system [34]. To
determine if altered MEK1 (and therefore ERK1) activity effects Scx expression in valve
precursor cells, a time course of AdV-caMEK1 and AdV-dnMEK1 treatments were
performed. At 48 hours post infection, significant increases in Scx expression were observed
with AdV-dnMEK1 treatment, while in contrast Scx was decreased following AdV-caMEK1
infection (Figure 5B). In addition to changes in Scx expression, AdV-caMEK1 treatments
reduced CSPG expression, while AdV-dnMEK1 infections increased levels as determined
by Western blot (Figure 5C–D) and immunohistochemistry (Figure 5E–G) analysis.
Collectively, these data suggest that in heart valve precursor cells, MAPK signaling
negatively regulates Scx and CSPG expression, even in the absence of active endogenous
Tgfβ signaling.
3.5 Overexpression of Scx in mature human valve interstitial cells promotes proteoglycans
We have shown that Scx overexpression in avian valve precursor cells and porcine VICs
promotes expression of CSPGs (Figure 2). To further extend this using a more clinically
relevant model system, we infected human mitral VICs isolated from donor hearts [25] with
AdV-Scx, and examined levels of several proteoglycans and collagens abundantly expressed
in human myxomatous mitral valve disease. As expected with human samples, we observed
variability in gene expression fold changes by qPCR across the four independent non-
diseased samples. However, analysis showed a consistent trend towards increased
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expression of aggrecan, biglycan, decorin, fibromodulin, type I and II collagen and versican
in AdV-Scx-FLAG infected samples compared to AdV-GFP controls (Table 1). This data
shows that Scx gain of function can promote molecular phenotypes associated with
myxomatous valve disease in otherwise healthy human VICs.
3.6 Scx is increased in myxomatous mitral valves from human patients and mouse models
Mice carrying a homozygous or heterozygous knock in mutation for Fibrillin-1
(Fbn1C1039G) serve as a model for Marfan Syndrome and develop myxomatous changes in
mitral valves by post natal day (PND) 6.5 [19]. To determine if Scx expression is altered in
this established model of myxomatous disease, qPCR was performed on atrioventricular
canal regions isolated from Fbn1C1039G/C1039G and Fbn1 C1039G/+ mice. As shown in Figure
6A, Scx expression is significantly increased in Fbn1C1039G/C1039G mice at PND6. In
addition to mice, increased Scx expression was also observed in mitral VICs isolated from
two, out of three human patients [25] (Figure 6B). Together, this highlights the potential
pathophysiological impact of this study and suggests that Scx could play an important role
in mediating myxomatous mitral valve disease pathogenesis.
4. Discussion
The molecular mechanisms responsible for the regulation of the bHLH transcription factor
Scx, and associated downstream target genes during heart valve development remain
unknown. Here, we demonstrate that Scx is both necessary and sufficient for expression of
proteoglycans associated with the spongiosa layer, including CSPGs, in both embryonic and
mature valve cells. Similarly, Scx can promote a trend towards increased expression of
proteoglycans and collagens in VICs isolated from human mitral valves, thereby promoting
myxomatous mitral valve disease-like phenotypes. Dissection of molecular pathways
previously shown to regulate Scx in other systems reveals that Scx is regulated upstream by
canonical Tgfβ signaling to promote CSPG expression. Further, we show that activated
MAPK attenuates Tgfβ2-mediated Scx expression, and represses Scx mRNA and CSPGs in
the absence of Tgfβ2. Overall, these data support a positive role for Tgfβ-Smad as a
regulator of Scx and proteoglycan expression in embryonic and adult valve structures, and
demonstrate modulation of this pathway by MAPK. Further, we have identified a signaling
pathway that when altered, could underlie myxomatous mitral valve pathogenesis observed
in the human population.
It is well described that an abnormal abundance of proteoglycans, including CSPGs are a
histological hallmark of myxomatous valve disease, however mechanisms that establish and
maintain proteoglycan homeostasis in healthy developing and mature valve structures have
not been described. In this study we identify the bHLH transcription factor Scx as a
regulator of CSPG expression in immature valve precursor cells and mature valve interstitial
cells (Figures 1 and 2). In vitro, this is mediated upstream by Tgfβ2-Smad signaling (Figures
2 and 3) and although this has not been examined in vivo, Tgfβ2 (and Tgfβ3) is highly
expressed in VICs from early remodeling stages [35] consistent with Scx [18]. However,
Tgfβ1 is also sufficient to promote Scx in muscle and cardiac fibroblasts [14, 17, 29–31] and
therefore as a secretory growth factor, it is plausible that Tgfβ1 from surrounding valve
endothelial cells [35] could act upon Scx in VICs in vivo. Consistent with Tgfβ1 as a
positive regulator of Scx, we show that Scx is reduced in hearts from Tgfβ2−/− mice (Figure
3B). Interestingly, Tgfβ2−/− mice have valve remodeling defects associated with leaflet
thickening and increased proteoglycan deposition by E18.5 [20]; contradictory to findings
presented from this study (Figure 3). However, VIC proliferation is increased in Tgfβ2−/−
mice from as early as E14.5, and therefore it is possible that the over abundance of
proteoglycans is secondary to increased cell number, and independent of reduced, but not
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absent Scx expression (Figure 3B). Our data shows that CSPGs brevican, neurocan, decorin,
biglycan and not aggrecan are significantly reduced in valves from Scx−/− mice (Figure 1).
However only aggrecan is significantly increased in response to Tgfβ2 treatment of post
natal mitral valve explants (Figure 2) consistent with previous tendon studies [36]. Therefore
it is considered that similar to previous findings in tendons and cardiac fibroblasts, [14, 17,
29–31] other Tgfβ ligands may play a role in regulating Scx-mediated CSPG expression in
the valves.
Studies have shown that formation of highly organized valve structures is dependent on the
tight regulation of signaling pathways in a temporal and spatial manner [1]. In this study we
have not only identified that Tgfβ2-Smad signaling positively regulates Scx and CSPG
expression (Figure 3), but show that MAPK signaling converges onto this pathway to have a
negative effect (Figures 4 and Figure 5). As Tgfβ2 treatment does not affect ERK activity
(Figure 4A), and MEK1 regulates Scx in the absence of Tgfβ2 treatment (Figure 4B), it is
likely that MAPK can function as a repressor of Scx in a Tgfβ2-independent manner. Our
findings show that direct activation of dpERK1/2 negatively regulates Scx, while reduced
dpERK1/2 activity increases Scx (Figure 5B). In mesenchymal precursor cells of the
developing somites, the opposite is observed; active dpERK is crucial for Scx expression
[15], however, increased activity also induces expression of the dual specificity phosphatase
Mkp3. Thereby introducing a negative feedback loop to appropriately downregulate ERK-
induced Scx activation to restrict its expression during precursor cell specification and
differentiation [15]. In contrast to somites, increased Scx was not observed in valve
precursor cells at 4, 16 or 48 hours following AdV-caMEK1 infection (Figure 5A), and
therefore we are doubtful that similar feedback mechanisms are conserved within these two
precursor cell populations. However, it cannot be excluded that phosphatase activity is
important for modulating dpERK1/2 activity in valves in order to regulate appropriate levels
of Scx and establish formation of the proteoglycan-rich spongiosa layer.
Findings in Figure 5 suggest that direct manipulation of MEK1 suppresses Scx in the
absence of exogenous Tgfβ2 signaling, however there are several pieces of data to suggest
that pERK1/2 as a kinase does not directly regulate Scx expression through protein
phosphorylation events. First, manipulation of MEK1/2 lead to changes in Scx at the
transcript level. Second, prediction software did not reveal ERK1/2 phosphorylation sites
within the Scx sequence, and third, decreased Scx expression was not observed until 48
hours after Adv-caMEK1/2 treatment, which is longer than anticipated for a phosphorylation
event. It was therefore considered that pERK1/2 could positively regulate a repressor, or
negatively regulate an activator of Scx in a signaling cascade independent of Tgfβ activity.
However, our data in Figure 4B also suggests that ERK1/2 attenuates Tgfβ2-Smad-mediated
activation of Scx and therefore when Tgfβ signaling is active, ERK1/2 converges onto this
signaling pathway. While it remains unclear how this occurs, crosstalk between MAPK and
Smad has been reported in Xenopus [37] and murine cell lines [38] through ERK-mediated
phosphorylation of the Smad linker region that has been shown to both suppress [37] and
increase [38] transcriptional activation of downstream target genes.
While direct target genes regulated by Scx in heart valves remain unknown, Scx has
previously been shown to regulate ECM matrix proteins in other systems. In developing
chick limbs, Scx gain of function promotes Tenascin and Tendomodulin; two glycoproteins
highly expressed in tendons [9, 13, 39]. Although these studies have been informative in
identifying genes that change in response to Scx function, direct regulation was not been
reported. More recently, Czubryt and colleagues demonstrated molecular interactions and
transactivation of Scx with E-box sites within the proximal promoter region of COL1A2 in
cardiac fibroblasts [17]. This study also showed that Scx-mediated regulation of COL1A2 is
induced by TGFβ1 signaling, and dependent on Smad3 [17]. The mechanism(s) of how Scx
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regulates proteoglycans in heart valve precursor and interstitial cells as shown in this current
study is not yet clear. It is suggested that similar to COL1A2, Scx regulates specific
proteoglycan genes (Figure 1A)) through identified conserved E-box binding sites. Scx may
not regulate the transactivation of CSPGs alone, but form multi/hetero dimers with known
bHLH co-regulators including E2A proteins E12 and E47 [14, 17].
Formation of the stratified valve structures begins in the embryo with localized secretion of
collagens, proteoglycans and elastin by valve precursor cells within the developing tri-
laminar layers. Perturbations in this process either during development, or after birth can
lead to alterations in ECM distribution, improper valve biomechanics and valve dysfunction.
In myxomatous valve disease, changes in ECM abundance are associated with an abnormal
increase in proteoglycans [7] and this is commonly observed in patients with Marfan’s
syndrome. In mice null for Scx, ECM organization is perturbed and valves are significantly
thickened from as early as E16.5 [18]. However, as shown in Figure 1, proteoglycans are
reduced and cell number is lower in Scx−/− embryos. Therefore, we speculate that thickening
is the result of observed collagen fiber fragmentation and increased collagen deposition [18]
that may be reflective of a fibrotic valvulopathy.
Genetic causes of Marfan syndrome (fibrillin-1 (fbn1) mutations) and the Marfan’s
syndrome-like condition, Loeys-Dietz syndrome (TGFβ receptor 1/2 mutations) result in
increase TGFβ signaling [40, 41]. Affected Fbn1C1039G mice (and humans [42]) show
significant increases in Tgfβ signaling and treatment with neutralizing antibodies during
stages of embryonic endocardial cushion remodeling (E14.5-E17.5) rescues mitral valve
defects [19]. Therefore suggesting that increased Tgfβ signaling underlies disease
pathogenesis, and myxomatous mitral valve disease has origins during valvulogenesis and in
particular stages of cushion remodeling. Interestingly, both Smad2/3 and Erk1/2 are
increased in Fbn1C1039G mice and Marfan syndrome patients due to the paradoxical
activation of TGFβ signaling [43]. In this study we observed only a subtle, but significant
decreased in Scx expression (~30%) in E13.5 hearts from Tgfβ2+/− and Tgfβ2−/− mice
(Figure 3). This could be attributed to compensation by other Tgfβ ligands, but could also be
the result of an imbalance in the regulation of Scx by Erk1/2 and Smad2/3.
The role of Scx in myxomatous mitral valve disease has not been reported, yet this study
shows that Scx is regulated by Tgfβ2 and promotes proteoglycans in valve cells including
those from human subjects (Table 1); therefore recapitulating observations made in valves
surgically removed from myxomatous mitral valve disease patients at the time of
replacement surgery [7, 44] [4]. Mutations in Scx have not been described in the human
population, however our work (this study, [18]) shows t hat Scx function must be tightly
regulated in order to establish and maintain the matrix components that form the tri-laminar
valve structure. Further, our work has identified a novel target of Tgfβ signaling that could
mediate myxomatous changes in heart valve structures.
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Highlights
• Heart valves from Scx null mice have reduced proteoglycan expression.
• Scx is sufficient to promote proteoglycan expression in embryonic and mature
heart valve interstitial cells.
• Tgfβ2 treatment promotes Scx expression in embryonic and mature heart valve
interstitial cells.
• MAPK negatively regulates Scx-mediated regulation of proteoglycans
• Scx expression is increased in human patients and mouse models of
myxomatous heart valve disease.
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Figure 1. Proteoglycan expression is reduced in atrioventricular canal regions isolated from post
natal Scx−/− mice
(A) qPCR analysis to show fold changes in proteoglycan gene expression in atrioventricular
canal regions isolated from post natal Scx−/− mice compared to wild type littermate controls.
* p<0.05 using Student’s t-test, n=4. (B–E) Immunohistochemistry to detect chondroitin
sulfate proteoglycan (CSPG) expression (green) in mitral valves (arrows, B, C) and atria (D,
E) from post natal wild type (Scx+/+)(B, D) and Scx−/−(C, E) mice. Blue indicates DAPI-
stained cell nuclei, red indicates wheat germ agglutinin staining (cell membranes). mv,
tricuspid valve.
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Figure 2. Scleraxis overexpression in avian valve precursor cells and porcine valve interstitial
cells promotes chondroitin sulfate proteoglycan expression
(A) Western blot analysis to show CSPG expression in HH Stage 25 avian heart valve
precursor cell cultures following 48 hour infection with AdV-Scx-FLAG (Scx-FLAG) or
AdV-GFP (GFP). α-Tubulin was used as a loading control. (B) Densitometry quantitation of
Western blot shown in (A), *=p<0.05. (C–D) Immunohistochemistry to detect CSPG
expression (red) in porcine valve interstitial (VICs) cultures infected with AdV-GFP or
AdV-Scx-FLAG. Blue indicates DAPI-positive cell nuclei. (E) Quantitation of CSPG
immunoreactivity shown in C–D normalized to cell number per magnification field.
*=p<0.05 using Student’s t-test, n=3.
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Figure 3. Tgfβ2 regulates Scx expression in vitro and in vivo, and promotes chondroitin sulfate
proteoglycan expression
(A) qPCR analysis to show fold changes in Scx expression in avian valve precursor cells,
and C3H10T1/2 and NIH3T3 murine fibroblast cell lines treated with 200pM Tgfβ2 for 48
hours compared to BSA vehicle treated controls (n=3). (B) qPCR to show Scx expression in
E13.5 hearts from Tgfβ2+/− and Tgfβ2−/− mice compared to wild type (Tgfβ2+/+) littermate
controls. (C–D) Immunohistochemistry to detect CSPG expression (red) in avian valve
precursor cell cultures with BSA vehicle or 200pM Tgfβ2 treatment for 48 hours. (E–F)
Immunohistochemistry to detect CSPG expression (red) in porcine VIC cultures treated for
48 hours with BSA vehicle or 200pM Tgfβ2. Blue indicates DAPI-positive cell nuclei. (G,
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H) Quantitation of CSPG immunoreactivity in avian valve precursor cells (C, D) and
porcine VICs (E, F) treated with 200pM Tgfβ2 compared to BSA control. (*=p<0.05 using
oneway ANOVA plus a post-hoc test n=3.) (I) qPCR to show fold changes in Aggrecan
expression in mitral valve explants from Scx+/+ and Scx−/− PND1 pups treated with Tgfβ2
treatment or PBS vehicle for 48 hours. (*=p<0.05 Tgfβ2 versus PBS, #=p<0.05 Tgfβ2
treatment in Scx+/+ versus Scx−/− using Students t-test, n=3).
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Figure 4. MEK1 activation represses Tgfβ2-mediated Scx expression
(A) Western blot analysis to show phospho-Smad2 (pSmad) and diphosho-ERK1/2
(dpERK1/2) levels in avian valve precursor cell cultures treated with 200pM Tgfβ2 for 30
minutes, compared to BSA vehicle controls. Actin was used as a loading control (B) qPCR
analysis to show Scx expression in murine C3H10T1/2 cells pre-infected with AdV-GFP,
AdV-caMEK1, or AdV-dnMEK1 for 6 hours prior to 48 hour treatment with 200pM Tgfβ2
or BSA vehicle control. *=p<0.05 vs. GFP+BSA, #=p<0.05 vs. GFP+Tgfβ2 using one-way
ANOVA plus a post-hoc test.
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Figure 5. Activated MEK1 signaling represses Scx and chondroitin sulfate proteoglycan
expression in heart valve precursor cells
(A) Western blot analysis to show increased and decreased diphospho-ERK1/2 levels in
avian heart valve precursor cells infected for 48 hours with AdV-caMEK1 and AdV-
dnMEK1 respectively, compared to AdV-GFP controls. (B) qPCR to show fold changes in
Scx expression in avian valve precursor cells following AdV-caMEK1 and AdV-dnMEK1
infection for 4, 16 and 48 hours, compared to AdV-GFP controls (n=4), *=p<0.05. (C)
Representative Western Blot to indicate CSPG expression in avian valve precursor cells
following AdV-GFP, AdV-caMEK1 and AdV-dnMEK1 treatments for 48 hours. (D)
Densitometry quantitation of Western blot analysis in (C), *=p<0.05 using one-way
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ANOVA plus a post-hoc test. (E–G) Immunohistochemistry to detect CSPG expression in
avian VP cell cultures infected with AdV-GFP (E), AdV-caMEK1 (F) or AdV-dnMEK1
(G).
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Figure 6. Scx is increased in myxomatous mitral valves
(A) qPCR to show increased Scx expression in atrioventricular canal regions isolated from
PHD6 Fbn1C1039G/C1039G mice, compared to wild type littermate controls. (B) qPCR to
show changes in Scx expression in mitral VICs isolated from human patients diagnosed with
myxomatous mitral valve disease, compared to mitral VICs collected from four, non-
diseased hearts. *=p<0.05 using one-way ANOVA plus a post-hoc test.
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